Oncogenic protein interfaces: small molecules, big challenges
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein–protein interactions (PPIs) play a crucial role in numerous biological processes, including signal transduction, cell proliferation, growth, differentiation, apoptosis.303–305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“However, their suitability for tight and narrow PPI interfaces and poor selectivity limits their application in targeting PPIs.305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“PPIs have relatively large and amorphous interfaces, rather than small and well-defined crevices.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
In the citing paper
“Compared with targeting enzymes or receptors, however, the development of molecules targeting PPIs has been challenging [22–24].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 1
- Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1–9 (2011).
Cited by
Items 301–319 of 319
Développement d'outils pour l'étude des interactions protéine-protéine
Milhas, S. (2016) · theses.fr (ABES) · doi:10.70675/7dcf6f45z231cz483fzb8f5z5cd27c8b0499
Les méthyltransférases de la coiffe du MERS-CoV : étude fonctionnelle et recherches d'inhibiteurs
Aouadi, W. (2017) · theses.fr (ABES) · doi:10.70675/8e1435e3zc63az4f17z8e10zc76c0a7a533b
Structure-based design of antiviral drugs against respiratory viruses using in silico approaches
Ruano, L. C. (2024) · theses.fr (ABES) · doi:10.70675/434de13dz7ff8z46beza24ezfaf0740f7dea
Pep2Mol: 3D Molecule Generation Targeting Protein-Protein Interfaces with Diffusion ModelsPreprint
Yue, R., Yang, Z., Seabra, G. D. M., Li, C., & Li, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.28.734975
“Although small molecules offer a promising drug discovery strategy for modulating PPIs by targeting their interfaces, their development remains highly challenging Nero et al. [2014], Shin et al. [2020].”
Niu, M., Wang, Y., Wu, H., Chen, S., Guan, L., Yuan, H. S., Liu, J., Wang, Y., Li, S., Lou, M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00216
HighMorph: De Novo Cyclic Peptide Sequence Design via Protein–Protein Interaction Recapitulation
Lan, M., Zhang, C., Wang, W., Haomeng, H., Lin, H., Cao, S., Guo, J., & Duan, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01926
De Novo Design of Targeted Drugs by Precisely Programming Multiple Molecular Binding
Zhao, C., Jin, Y., Li, X., Shi, Z., Shi, W., Ge, S., Liu, D., & Dong, Y. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c15828
Meulendijks, M. H. N., Li, Y., Steiner, F. J., Klintrot, R., Schulte, C., Roose, S., Yeste‐Vázquez, A., Maric, H. M., Hennig, S., Paulussen, F. M., et al. (2026) · ChemistryEurope · doi:10.1002/ceur.70357
Guo, R., Norford, K., Xu, L., Wei, M., Wang, W., Halene, S., & Pyle, A. M. (2026) · Nature Communications · doi:10.1038/s41467-026-77982-3
“Our study is relevant to the emerging area of protein-protein interface targeting, which has vast potential for the development of new therapeutics 65,66 .”
BindingDB Entry 50003224: Targeting Eph/ephrin system in cancer therapy.
BindingDB (2020) · UC San Diego · doi:10.7270/q29026gx
BindingDB (2020) · UC San Diego · doi:10.7270/q2805593
BindingDB Entry 50018504: Targeting MYC: From understanding its biology to drug discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q2qz2g61
Metadata
- Authors
- Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W.
- Affiliations
- Australian Cancer Research Foundation (AU)
- The University of Melbourne (AU)
- Corresponding author
- Parker, Michael W.
- Venue
- Nature Reviews Cancer
- Published
- 2014-03-13
- Volume
- 14
- Issue
- 4
- Pages
- 248-262
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2003516462
- Cited by
- 312
- References
- 161
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 35 · 2023: 29 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 19 · 2018: 26 · 2017: 24 · 2016: 34 · 2015: 37 · 2014: 15
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, oncoprotein, small molecule modulators, drug discovery, undruggable targets, protein-protein interaction surfaces, cancer drug targets
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Drug Screening Assays, Antitumor, Humans, Neoplasms, Protein Binding, Surface Properties, Oncogene Proteins, Protein Interaction Domains and Motifs, Protein Interaction Maps, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.